Family Planning Access Program (2018-2023)

Since 2013, JSI has leveraged its over 30 years of leadership in health supply chain management to monitor various family planning (FP) pharmaceutical agreements negotiated by the Bill & Melinda Gates Foundation (the Foundation) with manufacturers. These agreements were enacted under the Family Planning 2020 initiative (FP2020) to reduce the public sector purchase price of three- and five-year contraceptive implants Jadelle® and Nexplanon®, respectively, and Sayana® Press, a subcutaneous three-month injectable of depot medroxyprogesterone (DMPA-SC), and thereby increase global access to the products and thus contraceptive choice.

The scope of this project has evolved. In 2020, this contract was extended to continue JSI’s work on DMPA-SC, the Coordinated Supply Planning (CSP) group, and implementation of the Global Family Planning Visibility and Analytics Network (GFPVAN) managed by the Reproductive Health Supplies Coalition (RHSC). Funded by the Foundation, the Family Planning Access Program (FPAP) inclusively encompasses JSI’s work to support and monitor progress towards these agreements. Specifically, this work includes:

• Monitoring global shipment volumes and related supply information for DMPA-SC, and using this information to update donors on progress under the agreements and support countries in strengthening their FP product supply chains;
• Leading and providing technical support to the Coordinated Supply Planning (CSP) group, a cross-organizational team that strives to prevent family planning (FP) commodity stock imbalances by using shared supply chain data and information to coordinate shipments and the allocation of resources within and among countries;
• Transitioning the CSP group and activities to the Consensus Planning Group (CPG) under the governance and management of the GFPVAN;
• Leading data and partner coordination for shipment allocation and prioritization for several products with short-term supply constraints to minimize risk of severe country and program-level shortages and stockouts;
• Collecting and reviewing supply plans for countries and programs to evaluate needs against requests, orders, and proactively flag funding gaps;
• Providing technical leadership to the Reproductive Health Supplies Coalition (RHSC) on the development and implementation of the Global Family Planning Visibility and Analytics Network (GFPVAN);
• Developing market analyses to share with donors and procurers and creating novel forecasting methods to create rolling, quarterly global product forecasts to share with manufacturers.

In June 2020, an addendum was added to the FPAP contract to conduct a rapid analysis of the effects of COVID-19 on supply chains for sexual and reproductive health (SRH) products. Working in partnership with RHSC, we undertook a six-month effort to assess the current constraints to SRH product availability created and exacerbated by COVID-19, looking at the end-to-end supply chain with a deep-dive focus in three countries (Ethiopia, Kenya, and Zambia). The goal was to create a community roadmap to help prioritize practical actions that can address both current, acute challenges related to SRH products and COVID-19, and also promote greater supply chain resiliency and more effective and coordinated community response in the longer term. This work concluded in March 2021 and aspects of the roadmap will be carried forward by RHSC.

In April of 2022, JSI established a new 2-year contract with RHSC that will carry forward and expand our support work for the GFPVAN, thus reducing the scope of our FPAP contract.